Since KP and PA infections comprise only a portion of the fewer than 5% of hospitalized patients found to have nosocomial infection in a point-prevalence study (1), a clinical trial would require a large number of patients and multiple clinical trial sites. This evidence concerns the gene NPPA and nosocomial infection.